Simulations Plus launches Version 7.0 of GastroPlus software for pharmaceutical industry

Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, has announced the launch of Version 7.0 of GastroPlus, the industry's gold standard software for the simulation of drug absorption, pharmacokinetics, and pharmacodynamics.

“Version 7.0 is the largest single upgrade in the history of GastroPlus. In this version, we have added three major new capabilities that we expect to expand the use of GastroPlus throughout the pharmaceutical industry and provide new functionality that we believe will attract researchers in environmental toxicology as well.”

Dr. Viera Lukacova, team leader for Simulation Technologies at Simulations Plus, said, "Version 7.0 is the largest single upgrade in the history of GastroPlus. In this version, we have added three major new capabilities that we expect to expand the use of GastroPlus throughout the pharmaceutical industry and provide new functionality that we believe will attract researchers in environmental toxicology as well."

GastroPlus Version 7.0 now incorporates:

• Drug-drug interaction
• Ocular drug delivery
• Nasal/pulmonary drug delivery
• Numerous expansions to the basic program and modules for additional user convenience

Walt Woltosz, chairman and chief executive officer of Simulations Plus, added: "The one advantage that some of our competition has had over GastroPlus has been drug-drug interaction. Now, after two years of working with Roche, we have released the most advanced drug-drug interaction capability in the industry. This required a major architectural change to the program, and Dr. Lukacova and her team have done a remarkable job of developing, testing, and documenting this new capability. At the same time, we have added two new market-expanding capabilities for simulating drug delivery to the eye and via nasal/pulmonary passages. We have potential customers working in these areas who have been eagerly waiting for this release. We are expecting additional sales in the very near future as a result of these capabilities. Especially noteworthy is the fact that all three of these new capabilities were developed under funded collaborations with top-five pharmaceutical companies, minimizing our capitalized expenses."